MSH2

MSH2 (MutS Homolog 2) is a human gene that encodes a protein crucial for DNA mismatch repair (MMR). The MSH2 protein is a central component of the MMR pathway, which is responsible for correcting errors that occur during DNA replication, such as base-base mismatches and small insertion-deletion loops.

Gene and Protein Structure The MSH2 gene is located on chromosome 2p21. It is highly conserved across species, reflecting its fundamental role in genome integrity. The MSH2 protein is a large, approximately 105 kDa protein that functions primarily as a heterodimer. It forms two key complexes in the MMR pathway:

• MutSα: This complex consists of MSH2 and MSH6. MutSα is the primary complex responsible for recognizing and binding to single base-pair mismatches and small insertion-deletion loops (typically 1-2 nucleotides).
• MutSβ: This complex consists of MSH2 and MSH3. MutSβ is specialized in recognizing larger insertion-deletion loops (typically 2-10 nucleotides).

Function in DNA Mismatch Repair The DNA mismatch repair pathway is critical for maintaining genomic stability. The MSH2-containing MutS complexes act as the initial recognition step:

1. Mismatch Recognition: Upon encountering a mispaired base or an insertion-deletion loop during DNA replication, either MutSα or MutSβ binds to the aberrant DNA structure.
2. Recruitment of Downstream Factors: This binding event triggers a conformational change in the MutS complex, which then recruits other MMR proteins, including the MutL homologs (such as MLH1 and PMS2), to the site of the mismatch.
3. Excision and Resynthesis: The recruited proteins form a larger complex that ultimately leads to the excision of the erroneous DNA segment and its subsequent resynthesis using the correct template strand, thus restoring the fidelity of the DNA sequence.

Clinical Significance Mutations in the MSH2 gene have profound clinical implications, primarily due to their association with increased cancer risk.

• Lynch Syndrome (HNPCC): Germline mutations in MSH2 are one of the most common causes of Lynch syndrome (hereditary nonpolyposis colorectal cancer). Lynch syndrome is an autosomal dominant inherited disorder characterized by a significantly elevated risk of various cancers, particularly colorectal cancer (CRC), endometrial cancer, ovarian cancer, gastric cancer, urinary tract cancer, and others. Individuals inheriting a mutated MSH2 allele have a functional MMR pathway initially, but if the remaining wild-type allele is lost or mutated in a somatic cell (following the "two-hit hypothesis"), the cell becomes MMR-deficient.
• Microsatellite Instability (MSI): Loss of MSH2 protein function, often due to a pathogenic mutation, results in a deficient MMR system. This deficiency leads to a hallmark genetic alteration called microsatellite instability (MSI). Microsatellites are short, repetitive DNA sequences prone to replication errors. In the absence of a functional MMR system, these errors accumulate, leading to changes in the length of microsatellite sequences. MSI is a recognized biomarker for identifying Lynch syndrome and is also observed in a subset of sporadic cancers.
• Cancer Development: The accumulation of mutations due to a deficient MMR system can affect tumor suppressor genes and oncogenes, driving uncontrolled cell growth and leading to cancer. Patients with MSH2-deficient tumors may have different responses to certain chemotherapies and immunotherapies compared to MMR-proficient tumors.
• Diagnosis and Screening: Genetic testing for MSH2 mutations is a critical component of diagnostic screening for Lynch syndrome in individuals with a family history of associated cancers or those whose tumors show evidence of MMR deficiency (e.g., by immunohistochemistry staining for MMR proteins or MSI testing).